AR064572A1 - DERIVATIVES OF PIRIDINE 2-REPLACED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER. - Google Patents

DERIVATIVES OF PIRIDINE 2-REPLACED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER.

Info

Publication number
AR064572A1
AR064572A1 ARP070105941A ARP070105941A AR064572A1 AR 064572 A1 AR064572 A1 AR 064572A1 AR P070105941 A ARP070105941 A AR P070105941A AR P070105941 A ARP070105941 A AR P070105941A AR 064572 A1 AR064572 A1 AR 064572A1
Authority
AR
Argentina
Prior art keywords
alkynyl
alkenyl
alkyl
group
radicals
Prior art date
Application number
ARP070105941A
Other languages
Spanish (es)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of AR064572A1 publication Critical patent/AR064572A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Uso de piridinas 2-sustituidas de la formula 1 y las sales farmacéuticamente aceptables de las piridinas 2-sustituidas de la formula 1, en terapia, en particular en terapia o tratamiento de enfermedades cancerosas. Se provee además una composicion farmacéutica que las comprende y su uso en la fabricacion de un medicamento para el tratamiento del cáncer. Reivindicacion 1: Compuestos de piridina 2-sustituidos caracterizados porque tiene la formula 1 y las sales farmacéuticamente aceptables de las piridinas 2-sustituidas de la formula (1) para usar en terapia en donde los índices y los sustituyentes son como se definen más abajo; X1, X2 son, en cada caso, uno de los dos miembros del anillo es N, el otro es C-H o C-halogeno; Y es un grupo - CH-R1-, -N-R1-, -O-, o -S-; R1, R2 están seleccionados, de modo independiente entre sí, del grupo que consiste en alquilo C1-10, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-12 y cicloalquenilo C4-10 donde los grupos alifáticos y/o alicíclicos de las definiciones radicales de R1 y R2 por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro restos Rv, que pueden ser iguales o diferentes entre sí, Rv está seleccionado del grupo que consiste en halogeno, ciano, alquilo C1-8, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-6, cicloalquenilo C4-6, hidroxilo, alcoxi C1-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloalquil C3-6-oxi, cicloalquenil C4-6-oxi, -C(=O)-A1, -C(=O)-O-A1, -C(=O)- N(A2)A1, C(A2)(=N-OA1), N(A2)A1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=O)m-A1, S(=O)m-O-A1 o S(=O)m-N(A2)A1, siendo posible también que dos radicales vecinales Rv sean juntos (=O) o (=S), o Rv sea fenilo, donde el resto de metilo puede llevar uno, dos o tres radicales que pueden ser iguales o diferentes entre sí y que están seleccionados del grupo que consiste en halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, haloalquilo C1-6, alcoxi C1-6, ciano, nitro, -C(=O)-A, - C(=O)-O-A, -C(=O)-N(A')A, C(A')(=N-OA) y N(A')A: donde m es 0, 1 o 2; A1, A2, A3, A y A' son, de modo independiente entre sí, hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8 o fenilo, donde los radicales orgánicos pueden estar parcial o totalmente halogenados o pueden estar sustituidos con halogeno, nitro, cianato, ciano y/o alcoxi C1-4, o A1 y A2 o A y A', respectivamente, junto con los átomos a los que están unidos son un heterociclo saturado, parcialmente insaturado o aromático de cinco o seis miembros que comprende uno, dos, tres o cuatro heteroátomos como miembros de anillo seleccionados del grupo que consiste en O, N y S; y donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radicales de Rv por su parte pueden estar parcial o completamente halogenados, R1 puede ser adicionalmente H; R1 y R2 también pueden formar, junto con el átomo de N o de C al que están unidos, un anillo saturado o insaturado o 5 o 6 miembros, que puede comprender O, S, carbonilo (C=O), sulfoxilo (-S[=O]-), sulfonilo (-SO2-) o un grupo N(Rx)-, como un miembro del anillo, donde Rx es H o alquilo C1-6, y/o donde el anillo formado puede comprender uno o varios sustituyentes seleccionados del grupo que consiste en halogeno, alquilo C1-6, haloalquilo C1-6 y oxi-alquilen C1-3-oxi; R3 está seleccionado del grupo que consiste en halogeno, ciano, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, alcoxi C1-4, alquenil C3-4-oxi, alquinil C3-4-oxi, alquil C1-6-tio, di-(alquil C1-6)amino y alquil C1-6-amino, donde los grupos alifáticos y/o alicíclicos de las definiciones radicales de R3 por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro radicales Rt, que pueden ser iguales o diferentes entre sí; Rt está seleccionado del grupo que consiste en halogeno, ciano, alquilo C1-8, alquenilo C2-10, alquinilo C2-10, hidroxilo, alcoxi C1-6, cicloalquilo C3-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloalquenilo C4-6, cicloalquil C3-6-oxi, cicloalquenil C4-6-oxi, -C(=O)-A13, -C(=O)-OA13, -C(=O)-N(A14)A13, C(A14)(=N-OA13), N(A14)A13, N(A14)-C(=O)-A13, N(A15)-C(=O)-N(A14)A13, S(=O)p-A13, S(=O)p-O- A13 y S(=O)p-N(A14)A13, siendo posible también que dos radicales vecinales Ru sean juntos (=O) o (=S), donde p es 0, 1 o 2; A13, A14 y A15 tienen, de modo independiente entre sí, los significados A1, A2 y A3 tal como se definio con anterioridad; y donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radicales de Rt por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos o tres radicales Rta, que pueden ser iguales o diferentes entre sí y que pueden tener los significados de Rt tal como se definio con anterioridad; R4 es un heterociclo mono- o bicíclico saturado, parcialmente insaturado o aromático de cinco, seis, siete, ocho, nueve o diez miembros que comprende uno, dos, tres o cuatro heteroátomos como miembros del anillo seleccionados del grupo que consiste en O, N y S y donde el heterociclo, por su parte, pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro radicales RU, que pueden ser iguales o diferentes entre sí, RU está seleccionado del grupo que consiste en halogeno, ciano, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, hidroxilo, alcoxi C1-6, cicloalquilo C3-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloalquenilo C4-6, cicloalquil C3-6-oxi, cicloalquenil C4-6-oxi, -C(=O)-A4, -C(=O)-OA4, -C(=O)-N(A5)A4, -C(=S)-N(A5)A4, C(A5)(=N-OA4), N(A5)A4, N(A5)-C(=O)-A4, N(A6)-C(=O)-N(A5)A4, S(=O)q-A4, S(=O)q-O-A4 y S(=O)q-N(A5)A4, siendo posible también que dos radicales vecinales Ru sean juntos (=O) o (=S), donde q es 0, 1 o 2; A4, A5 y A6 tienen, de modo independiente entre si, los significados de A1, A2 y A3 tal como se definio con anterioridad; y donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radicales de RU por su parte pueden estar parcial o totalmente halogenados o puede llevar uno, dos o tres radicales RUa, que pueden ser iguales o diferentes entre sí y que pueden tener los significados de RU tal como se definio con anterioridad; R4 también pueden ser: ciano, C(=Z)ORa, C(=Z)NRzRb, C(=Z)NRz-ORa, C(=Z)NRa-NRzRb, C(=Z)Ra, CRaRb-ORz, CRaRb-NRzRc, ON(=CRaRb), O-C(=Z)Ra, NRaRb1, NRa(C(=Z)Rb), NRa(C(=Z)-ORb), NRa(C(=Z)-NRZRb) NRa(N=CRaRb), Nra-NRZRb o NRz-Ora, donde Z es O, S, NRa1, NORa1 o N-NRz1Rc1; Ra, Ra1, Rb, Rc, Rc1 son, de modo independiente entre sí, hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 o cicloalquenilo C4-6; Rb1 tiene los significados de Rb tal como se definio con anterioridad, excepto por hidrogeno; y Rz, Rz1 tienen, de modo independiente entre sí, los significados de Ra tal como se definio con anterioridad y pueden ser adicionalmente -CO-Ra2, donde Ra2 tiene los significados de Ra tal como se definio con anterioridad; donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radicales de Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz y Rz1 por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro radicales Rw, que pueden ser iguales o diferentes entre si; Rw es halogeno, ciano, alquilo C1-8, alquenilo C2-10, alquinilo C2-10, alcoxi C1-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloalquilo C3-6, cicloalquenilo C3-6, cicloalcoxi C3-6, cicloalquenil C3-6-oxi, y donde dos de los radicales Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz o Rz1 pueden formar, junto con los átomos a los que están unidos, un heterociclo saturado, parcialmente insaturado o aromático de cinco o seis miembros que comprende uno, dos, tres o cuatro heteroátomos como miembros del anillo seleccionados del grupo que consiste en O, N y S; el anillo B es fenilo o un hetarilo de cinco o seis miembros que comprende 1, 2 o 3 heteroátomos como miembros del anillo seleccionados del grupo que consiste en O, N y S; n es 1, 2, 3, 4 o 5; L está seleccionado del grupo que consiste en halogeno, ciano, cianato, (OCN), alquilo C1-10, alquenilo C2-10, alquinilo C2-10, alcoxi C1-6, hidroxilo, alcoxi C1-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloaIquilo C3-6, cicloalquenilo C4-6, cicloalquil C3-6-oxi, cicloalquenil C4-6-oxi, nitro, -C(=O)-A7, -C(=O)-O-A7, -C(=O)-N(A8)A7, -C(=S)-N(A8)A7, -C(=NA8)-SA7, C(A8)(=N-OA7), N(A8)A7, N(A8)-C(=O)A7, N(A9)-C(=O)-N(A8)A7, S(=O)r-A7, S(=O)r-O-A7 y S(=O)r- N(A8)A7, donde L puede ser idéntico o diferente, cunado n es 2, 3, 4, o 5 y donde r es 0, 1 o 2; A7, A8, A9 tienen, de modo independiente entre sí, los significados de A1, A2 y A3 tal como se definio con anterioridad; donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radicales de L por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro radicales RL, que pueden ser iguales o diferentes entre si; RL está seleccionado del grupo que consiste en halogeno, ciano, alquilo C1-10, alquenilo C2-10, alquinilo C2-10, hidroxilo, alcoxi C1-6, alquenil C2-10-oxi, alquinil C2-10-oxi, cicloaIquilo C3-6, cicloalquenilo C4-6, cicloalquil C3-6-oxi, cicloalquenil C4-6-oxi, -C(=O)-A10, -C(=O)-O-A10, -C(=O)-N(A11)A10, -C(A11)(=N-OA10), N(A11)A10, N(A11)-C(=O)A10, N(A12)-C(=O)-N(A11)A10, S(=O)s-A10, S(=O)s-O-A10 y S(=O)s-N(A11)A10, siendo posible también que dos radicales vecinales RL sean juntos (=O) o (=S), donde s es 0,1 o 2; y A10, A11 y A12 tienen, de modo independiente entre sí, los significados de A1, A2 y A3 tal como se definio con anterioridad; y donde los grupos alifáticos, alicíclicos y/o aromáticos de las definiciones radícales de RL por su parte pueden estar parcial o totalmente halogenados o pueden llevar uno, dos, tres o cuatro radicales RLA, que pueden ser iguales o diferentes entre sí y que pueden tener los significados de RL tal como se definio con anterioridad.Use of 2-substituted pyridines of the formula 1 and the pharmaceutically acceptable salts of the 2-substituted pyridines of the formula 1, in therapy, in particular in therapy or treatment of cancerous diseases. A pharmaceutical composition is also provided which comprises them and their use in the manufacture of a medicament for the treatment of cancer. Claim 1: 2-substituted pyridine compounds characterized in that it has the formula 1 and the pharmaceutically acceptable salts of the 2-substituted pyridines of the formula (1) for use in therapy wherein the indices and substituents are as defined below; X1, X2 are, in each case, one of the two members of the ring is N, the other is C-H or C-halogen; Y is a group - CH-R1-, -N-R1-, -O-, or -S-; R1, R2 are independently selected from the group consisting of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-12 cycloalkyl and C4-10 cycloalkenyl where the aliphatic and / or alicyclic groups of the radical definitions of R1 and R2 on the other hand may be partially or totally halogenated or may carry one, two, three or four Rv residues, which may be the same or different from each other, Rv is selected from the group consisting of halogen, cyano, C1-8 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-6 cycloalkyl, C4-6 cycloalkenyl, hydroxy, C1-6 alkoxy, C2-10-oxy alkenyl, C2-10-oxy alkynyl, C3-6 cycloalkyl -oxy, C4-6-oxycycloalkenyl, -C (= O) -A1, -C (= O) -O-A1, -C (= O) - N (A2) A1, C (A2) (= N -OA1), N (A2) A1, N (A2) -C (= O) -A1, N (A3) -C (= O) -N (A2) A1, S (= O) m-A1, S (= O) mO-A1 or S (= O) mN (A2) A1, being also possible that two neighborhood radicals Rv are together (= O) or (= S), or Rv is phenyl, where the rest of methyl can carry one, two or three radicals that can be the same or different from each other and are selected from the group consisting of halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, C 1-6 alkoxy, cyano, nitro , -C (= O) -A, - C (= O) -OA, -C (= O) -N (A ') A, C (A') (= N-OA) and N (A ') A: where m is 0, 1 or 2; A1, A2, A3, A and A 'are, independently of each other, hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl or phenyl, where the radicals organic may be partially or totally halogenated or may be substituted with halogen, nitro, cyanate, cyano and / or C1-4 alkoxy, or A1 and A2 or A and A ', respectively, together with the atoms to which they are attached are a saturated, partially unsaturated or aromatic heterocycle of five or six members comprising one, two, three or four heteroatoms as ring members selected from the group consisting of O, N and S; and where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of Rv on the other hand may be partially or completely halogenated, R1 may additionally be H; R1 and R2 may also form, together with the N or C atom to which they are attached, a saturated or unsaturated ring or 5 or 6 members, which may comprise O, S, carbonyl (C = O), sulfoxyl (-S [= O] -), sulfonyl (-SO2-) or an N (Rx) group -, as a ring member, where Rx is H or C1-6 alkyl, and / or where the formed ring may comprise one or more substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl and oxy-C1-3alkylene; R 3 is selected from the group consisting of halogen, cyano, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 1-4 alkoxy, C 3-4 alkenyl, C 3-4 alkynyl , C1-6-thio alkyl, di- (C1-6 alkyl) amino and C1-6-amino alkyl, where the aliphatic and / or alicyclic groups of the radical definitions of R3 on the other hand may be partially or totally halogenated or may carry one, two, three or four radicals Rt, which may be the same or different from each other; R t is selected from the group consisting of halogen, cyano, C 1-8 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxy, C 1-6 alkoxy, C 3-6 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl -oxy, C4-6 cycloalkenyl, C3-6-oxycycloalkyl, C4-6-oxycycloalkenyl, -C (= O) -A13, -C (= O) -OA13, -C (= O) -N (A14 ) A13, C (A14) (= N-OA13), N (A14) A13, N (A14) -C (= O) -A13, N (A15) -C (= O) -N (A14) A13, S (= O) p-A13, S (= O) pO- A13 and S (= O) pN (A14) A13, it being possible that two neighborhood radicals Ru are together (= O) or (= S), where p is 0, 1 or 2; A13, A14 and A15 have, independently of each other, the meanings A1, A2 and A3 as defined above; and where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of Rt on the other hand may be partially or totally halogenated or may carry one, two or three Rta radicals, which may be the same or different from each other and that may have meanings of Rt as defined above; R4 is a saturated, partially unsaturated or aromatic mono- or bicyclic heterocycle of five, six, seven, eight, nine or ten members comprising one, two, three or four heteroatoms as ring members selected from the group consisting of O, N and S and where the heterocycle, in turn, may be partially or totally halogenated or may carry one, two, three or four radicals RU, which may be the same or different from each other, RU is selected from the group consisting of halogen, cyano , C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, hydroxy, C1-6 alkoxy, C3-6 cycloalkyl, C2-10-oxy alkenyl, C2-10-oxy alkynyl, C4-6 cycloalkenyl, C3- cycloalkyl 6-oxy, C4-6-oxycycloalkenyl, -C (= O) -A4, -C (= O) -OA4, -C (= O) -N (A5) A4, -C (= S) -N (A5) A4, C (A5) (= N-OA4), N (A5) A4, N (A5) -C (= O) -A4, N (A6) -C (= O) -N (A5) A4, S (= O) q-A4, S (= O) qO-A4 and S (= O) qN (A5) A4, being also possible that two neighborhood radicals Ru are together (= O) or (= S) , where q is 0, 1 or 2; A4, A5 and A6 have, independently of each other, the meanings of A1, A2 and A3 as defined above; and where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of RU on the other hand may be partially or totally halogenated or may carry one, two or three RUa radicals, which may be the same or different from each other and that may have meanings of RU as defined above; R4 can also be: cyano, C (= Z) ORa, C (= Z) NRzRb, C (= Z) NRz-ORa, C (= Z) NRa-NRzRb, C (= Z) Ra, CRaRb-ORz, CRaRb-NRzRc, ON (= CRaRb), OC (= Z) Ra, NRaRb1, NRa (C (= Z) Rb), NRa (C (= Z) -ORb), NRa (C (= Z) -NRZRb) NRa (N = CRaRb), Nra-NRZRb or NRz-Ora, where Z is O, S, NRa1, NORa1 or N-NRz1Rc1; Ra, Ra1, Rb, Rc, Rc1 are, independently of one another, hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl or C4-6 cycloalkenyl; Rb1 has the meanings of Rb as defined above, except for hydrogen; and Rz, Rz1 have, independently of each other, the meanings of Ra as defined above and may additionally be -CO-Ra2, where Ra2 has the meanings of Ra as defined above; where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz and Rz1 on the other hand can be partially or totally halogenated or can carry one, two, three or four radicals Rw, which may be the same or different from each other; R w is halogen, cyano, C 1-8 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-6 alkoxy, C 2-10 alkenyl, C 2-10 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C3-6 cycloalkoxy, C3-6-oxycycloalkenyl, and where two of the radicals Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz or Rz1 can form, together with the atoms to which they are attached, a saturated heterocycle, partially unsaturated or aromatic five or six members comprising one, two, three or four heteroatoms as ring members selected from the group consisting of O, N and S; ring B is phenyl or a five or six membered hetaryl comprising 1, 2 or 3 heteroatoms as ring members selected from the group consisting of O, N and S; n is 1, 2, 3, 4 or 5; L is selected from the group consisting of halogen, cyano, cyanate, (OCN), C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C1-6 alkoxy, hydroxyl, C1-6 alkoxy, C2-10 alkenyl oxy, C2-10-alkynyl, cycloaC3-6 alkyl, C4-6 cycloalkenyl, C3-6-oxycycloalkyl, C4-6 cycloalkenyl, nitro, -C (= O) -A7, -C (= O) -O-A7, -C (= O) -N (A8) A7, -C (= S) -N (A8) A7, -C (= NA8) -SA7, C (A8) (= N-OA7) , N (A8) A7, N (A8) -C (= O) A7, N (A9) -C (= O) -N (A8) A7, S (= O) r-A7, S (= O) rO-A7 and S (= O) r- N (A8) A7, where L can be identical or different, when n is 2, 3, 4, or 5 and where r is 0, 1 or 2; A7, A8, A9 have, independently of each other, the meanings of A1, A2 and A3 as defined above; where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of L on the other hand may be partially or totally halogenated or may carry one, two, three or four RL radicals, which may be the same or different from each other; RL is selected from the group consisting of halogen, cyano, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, hydroxyl, C1-6 alkoxy, C2-10 alkenyl, C2-10 alkynyl, C3 cycloalkyl -6, C4-6 cycloalkenyl, C3-6-oxy cycloalkyl, C4-6-oxycycloalkenyl, -C (= O) -A10, -C (= O) -O-A10, -C (= O) -N (A11) A10, -C (A11) (= N-OA10), N (A11) A10, N (A11) -C (= O) A10, N (A12) -C (= O) -N (A11) A10, S (= O) s-A10, S (= O) sO-A10 and S (= O) sN (A11) A10, it is also possible that two neighborhood radicals RL are together (= O) or (= S) , where s is 0.1 or 2; and A10, A11 and A12 have, independently of each other, the meanings of A1, A2 and A3 as defined above; and where the aliphatic, alicyclic and / or aromatic groups of the radical definitions of RL on the other hand may be partially or totally halogenated or may carry one, two, three or four RLA radicals, which may be the same or different from each other and that may have the meanings of RL as defined above.

ARP070105941A 2006-12-28 2007-12-27 DERIVATIVES OF PIRIDINE 2-REPLACED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER. AR064572A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127317 2006-12-28

Publications (1)

Publication Number Publication Date
AR064572A1 true AR064572A1 (en) 2009-04-08

Family

ID=39273079

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105941A AR064572A1 (en) 2006-12-28 2007-12-27 DERIVATIVES OF PIRIDINE 2-REPLACED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER.

Country Status (3)

Country Link
AR (1) AR064572A1 (en)
TW (1) TW200835487A (en)
WO (1) WO2008080938A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514260B1 (en) 2000-03-15 2003-02-04 Sdgi Holdings, Inc. Methods and instruments for laparoscopic spinal surgery
CA2734486A1 (en) * 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
NZ596123A (en) * 2009-05-19 2014-08-29 Dow Agrosciences Llc Compounds and methods for controlling fungi
FR2978768B1 (en) * 2011-08-05 2014-11-28 Saint Gobain Isover SINKING COMPOSITION FOR MINERAL WOOL BASED ON SUCROSE REDUCER AND HYDROGEN SACCHARIDE, AND INSULATING PRODUCTS OBTAINED

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK101199A3 (en) * 1997-02-10 2000-10-09 Pfizer Prod Inc 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines, their use and pharmaceutical compositions based thereupon
ES2240661T3 (en) * 2001-07-05 2005-10-16 Pfizer Products Inc. SULFONIL-HETEROARIL-TRIAZOLES AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS.
US7244735B2 (en) * 2003-12-02 2007-07-17 Vertex Pharmaceuticals Inc. Heterocyclic protein kinase inhibitors and uses thereof
DE502005002116D1 (en) * 2004-06-25 2008-01-10 Basf Ag 2, 4, 5, 6-SUBSTITUTED PYRIDINES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE CONTROL OF HARMFUL

Also Published As

Publication number Publication date
TW200835487A (en) 2008-09-01
WO2008080938A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
HRP20210871T1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
AR055669A1 (en) DERIVATIVES OF 3H - IMIDAZO [4, 5 -B] PIRIDINE AS SELECTIVE INHIBITORS OF GSK3, METHODS AND INTERNEDIARIES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NEURODE DISEASE.
BR112018008880A2 (en) As a TLR7 agonist of the 7- (thiazol-5-yl) pyrrolopyrimidine compound
AR059957A1 (en) DERIVATIVES OF SPIROINDOLINONE, METHODS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CANCER.
RU2016134751A (en) COMPOUNDS
UY29199A1 (en) TIAZOL DERIVATIVES, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
AR053195A1 (en) INHIBITING COMPOUNDS OF DIPEPTIDIL PEPTIDASA-IV METHODS TO PREPARE THE SAME AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE AGENT
AR064572A1 (en) DERIVATIVES OF PIRIDINE 2-REPLACED, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER.
AR068756A1 (en) PEPTIDIC COMPOUNDS, PHARMACEUTICAL FORMULATION AND ITS USES AS MODULATORS OF THE HEPATITIS C VIRUS
AR050952A1 (en) INDAZOLONA DERIVATIVES; PROCESSES FOR OBTAINING; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF ENZYME 11BETA - HSD1.
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
UY37842A (en) MCL-1 MACROCYCLIC INHIBITORS AND METHODS OF USE
CU20130142A7 (en) PREPARATION OF HIGH PURITY GADOBUTROL
ECSP109935A (en) PYRIMIDINE MORFOLINE DERIVATIVES USED IN DISEASES RELATED TO MTOR QUINASA AND / OR PI3K
DOP2014000055A (en) PIRROLOPIRIMIDINE AND PURINE DERIVATIVES
ECSP20018703A (en) MCL-1 MACROCYCLIC INHIBITORS AND METHODS OF USE
JP2013528600A5 (en)
RU2008145714A (en) PURINE DERIVATIVES AS AN ADENOSINE RECEPTOR ACTIVATOR
AR079648A1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
AR051997A1 (en) TRICYCLIC HETEROCICLES, ITS OBTAINING AND USE OF THE SAME C OMO PHARMACEUTICAL AGENTS
AR084935A1 (en) DERIVATIVES OF TYPE AZAINDAZOL OR DIAZAINDAZOL AS MEDICINES
AR072906A1 (en) MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL
TW200700387A (en) 1-benzylindole-2-carboxamide derivatives
UY29002A1 (en) NEW HIDANTOINE DERIVATIVES, PARASU PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY
AR069772A1 (en) HETEROCICLIC DERIVATIVES, A PHARMACEUTICAL COMPOSITION AND A GAME THAT UNDERSTAND AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A PARASITARY INFECTION.

Legal Events

Date Code Title Description
FB Suspension of granting procedure